Home » Topics » Conferences

Conferences
RSS

Idec further defines clinical usage of IDEC-Y2B8

Dec. 10, 1998

ImClone's anti-KDR antibody, a novel angiogenesis inhibitor, featured at ASH

Dec. 10, 1998

Avigen presents results of preclinical testing of hemophilia gene therapy and plans clinical trials

Dec. 10, 1998

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Dec. 10, 1998

News from ASH: lisofylline in BMT

Dec. 10, 1998

CMA-676 shows efficacy and excellent tolerability in patients with AML

Dec. 9, 1998

Excellent results obtained in AML patients receiving Maxamine plus IL-2

Dec. 9, 1998

Banyu conducts PK and metabolic studies of topoisomerase I inhibitor

Dec. 9, 1998

Cerus presents preclinical data on RBC pathogen inactivation system and begins clinical trials

Dec. 9, 1998

Preliminary report of therapeutic efficacy with 506U78 in leukemia patients

Dec. 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...